Skip to content

Q4 FY25 Earnings Results

Q4 FY25 earnings, Jan–Mar 2025: 6,076 Indian listed companies have reported; median profit growth is −0.4% on last year. Quarter ended 31 Mar 2025.

Clear filters 201–270 of 270
CompanyRevenue (₹ Cr)Profit (₹ Cr)Per share8Q profit
Symbol Sector Reported YoY QoQ Reported YoY EPS vs consensus Trend
CENTENIALSURGICALSUTURELTD Healthcare13up+10.5%up+9.1%−1down−721.1%−3.23No estimate
SHUKRAPHAR Shukra Pharmaceuticals LtdHealthcare13up+18.2%up+18.2%5up+25.0%0.12No estimate
TYCHEINDUSTRIESLTD Healthcare12down−12.9%down−30.3%1down−55.2%0.92No estimate
GUJARATTERCELABORATORIESLTD Healthcare12up+0.9%down−2.8%−3down−727.8%−4.57No estimate
VIVOBIOT Vivo Bio Tech LtdHealthcare12up+4.5%up+0.7%1up+43.2%0.62No estimate
ZENOTECHLABORATORIESLTD Healthcare12up+33.2%up+7.9%1up+86.4%0.20No estimate
Cian Healthcare Ltd Healthcare12down−80.6%n/a−8n/a−3.09No estimate
JFLLIFE JFL Life Sciences LtdHealthcare12down−45.9%down−44.8%0down−93.3%0.02No estimate
ACCRETIONNUTRAVEDALTD Healthcare11n/an/a2n/a3.51No estimate
VILINBIO Vilin Bio Med LtdHealthcare10up+26.5%n/a0n/a0.07No estimate
JEEVANSCIENTIFICTECHNOLOGYLTD Healthcare10down−9.1%down−19.6%−1n/a−0.82No estimate
Anus Laboratories Ltd Healthcare9down−35.7%down−94.6%85up+19.7%3.99No estimate
GKB GKB Ophthalmics LtdHealthcare8up+14.5%up+13.2%−2n/a−4.92No estimate
BIOFILCHEM Biofil Chemicals & Pharmaceuticals LtdHealthcare8down−45.1%down−41.2%0down−20.0%0.12No estimate
Solvay Pharma India Ltd(merged) Healthcare8up+45.9%down−3.6%3n/a2.16No estimate
CONCORDDRUGSLTD Healthcare8down−45.0%down−26.1%0n/a0.01No estimate
VASUNDHARARASAYANSLTD Healthcare8down−30.3%down−12.0%0down−78.9%1.42No estimate
AUROLABORATORIESLTD Healthcare7down−38.6%up+142.6%0down−83.2%0.63No estimate
Perk Pharmaceuticals Ltd Healthcare7n/aup+29.2%1n/a0.49No estimate
KMSMEDISURGILTD Healthcare6down−9.1%n/a0n/a1.09No estimate
KREBSBIO Krebs Biochemicals & Industries LtdHealthcare6down−49.0%down−46.8%−8n/a−3.84No estimate
RAJNISHWELLNESSLTD Healthcare6down−78.6%down−36.3%0down−264.3%0.00No estimate
VEERHEALTHCARELTD Healthcare6up+66.8%up+46.4%0n/a−0.05No estimate
PHAARMASIALTD Healthcare5down−45.6%up+15.0%−1down−212.8%−0.78No estimate
BERYLDRUGSLTD Healthcare5up+62.6%down−3.3%0n/a0.30No estimate
PARMAXPHARMALTD Healthcare5up+13.4%down−23.1%−1n/a−3.98No estimate
PHARMAIDSPHARMACEUTICALSLTD Healthcare5down−17.9%up+1.3%−5n/a−1.12No estimate
ISHITADRUGSINDUSLTD Ishita Drugs & Industries LtdHealthcare5up+1.3%up+10.4%0up+3.6%0.97No estimate
DESHRAKSHAKAUSHDHALAYALTD Healthcare4up+76.3%up+133.5%0up+125.0%0.81No estimate
SHREEPACETRONIXLTD Healthcare4down−35.6%up+17.9%0down−68.5%1.25No estimate
GUJINJECLTD Gujarat Inject (Kerala) LtdHealthcare4down−21.8%up+34.6%0up+75.0%0.00No estimate
DECIPHERLABSLTD Healthcare4down−66.9%down−39.7%−4down−442.5%−4.07No estimate
ZENITHHEALTHCARELTD Healthcare3up+11.7%up+48.5%0n/a0.02No estimate
A D S Diagnostic Ltd Healthcare3down−43.4%up+29.6%0down−78.8%0.32No estimate
VISTAPHARMACEUTICALSLTD Healthcare3up+3.2%up+26.2%−2down−1,766.7%−0.41No estimate
SHREEGANESHBIOTECHINDIALTD Healthcare3down−20.4%down−79.1%−1down−275.9%−0.02No estimate
Sangam Health Care Products Ltd Healthcare3down−13.1%down−10.1%0n/a0.13No estimate
MEDINOVADIAGNOSTICSERVICELTD Medinova Diagnostic Services LtdHealthcare3up+0.8%up+11.6%10.0%0.60No estimate
Medinova Diagnostic Services Ltd Healthcare3up+0.8%up+11.6%10.0%0.60No estimate
UNJHAFORMULATIONSLTD Healthcare2down−44.9%down−35.1%0n/a−0.92No estimate
TRANSCHEMLTD Healthcare2up+490.2%up+1,052.4%1down−41.6%0.60No estimate
Transchem Ltd Healthcare2up+490.2%up+1,052.4%1down−41.6%0.60No estimate
BRAWNPHARMACEUTICALSLTD Brawn Biotech LtdHealthcare2down−34.5%down−41.1%0n/a−1.63No estimate
AMBALALSA Ambalal Sarabhai Enterprises LtdHealthcare2up+74.7%up+47.9%−5down−205.5%−0.65No estimate
COLINZLABORATORIESLTD Healthcare1down−11.0%down−1.4%0up+7.1%0.60No estimate
GANGAPHARMACEUTICALSLTD Healthcare1down−6.3%n/a0up+100.0%0.12No estimate
SUVEN Suven Life Sciences LtdHealthcare1down−50.0%down−50.0%−44n/a−2.01No estimate
ACHYUTHEALTHCARELTD Healthcare1n/an/a0n/a0.01No estimate
MEDICAPQ Medi Caps LtdHealthcare1down−54.8%up+242.3%1up+9.2%0.57No estimate
Span Divergent Ltd Healthcare1down−81.8%down−71.1%−1down−217.0%−1.63No estimate
VIVANZABIOSCIENCESLTD Healthcare0down−89.1%down−68.0%−1n/a−0.25No estimate
VENMAXDRUGSPHARMACEUTICALSLTD Venmax Drugs & Pharmaceuticals LtdHealthcare0n/aup+65.0%1up+1,460.0%1.49No estimate
VANTABIOSCIENCELTD Healthcare0down−90.7%n/a−1n/a−2.17No estimate
GENOMICVALLEYBIOTECHLTD Healthcare0n/aup+18.2%0n/a−0.26No estimate
RUBRAMEDICAMENTSLTD Centuple Global LtdHealthcare0down−46.8%up+150.0%0n/a0.11No estimate
ORTINGLOBE Ortin Global LtdHealthcare0down−70.0%up+200.0%0n/a−0.20No estimate
TRANSPACTENTERPRISESLTD Healthcare0n/an/a0n/a1.29No estimate
SHYAMAINFOLTD Shyama Computronics and Services LtdHealthcare0up+16.7%up+16.7%0up+12.5%0.09No estimate
CHEMOPHARMALABORATORIESLTD Starsource Multitrade LtdHealthcare0n/an/a0n/a−2.27No estimate
TRIOCHEMPRODUCTSLTD Healthcare0n/an/a0down−240.6%−18.37No estimate
GENESISIBRCINDIALTD CCME Global LtdHealthcare0n/an/a0n/a−0.02No estimate
KABRADRUGSLTD Healthcare0n/an/a0n/a0.16No estimate
BACILPHARMALTD Healthcare0n/an/a0n/a0.01No estimate
KAMRONLABORATORIESLTD Adline Chem Lab LtdHealthcare0n/an/a0n/a0.36No estimate
REKVINALABORATORIESLTD Rekvina Labs LtdHealthcare0n/an/a0n/a−0.03No estimate
RAYMEDLABSLTD Cresanto Global LimitedHealthcare0n/an/a0n/a0.16No estimate
MPS Pharmaa Ltd Healthcare0n/an/a0n/a−0.15No estimate
NECLIFE Nectar Lifescience LtdHealthcare0down−100.0%n/a−130down−13,100.0%−5.80No estimate
TAKE Take LtdHealthcare0n/an/a−5n/a−0.33No estimate
Harleystreet Pharmaceuticals Ltd(merged) Healthcare—n/an/a177up+13.5%5.63No estimate

About Q4 FY25 earnings data

When are Q4 FY25 results announced?
Q4 FY25 covers the Jan–Mar 2025 quarter. Indian listed companies have up to 45 days after a quarter closes to file their results — 60 days for the January–March quarter — so results arrive in a wave over the weeks that follow rather than all at once. A quarter that has only just ended will look sparse and fill in.
Why do some Q4 FY25 growth figures show "n/a" instead of a percentage?
Growth is left blank whenever the comparison period was not profitable. A percentage change measured from a loss is arithmetic without meaning — a swing from a ₹10 crore loss to a ₹10 crore profit is not "200% growth", and publishing it as such would flatter the company. The reported figures for both periods are still shown, so the change is there to read directly.
Does the beat/miss verdict cover every company?
No analyst consensus was available for Q4 FY25, so no beat/miss verdict is shown. Revenue and profit growth are taken from reported results and cover every company in the table.
What counts as an in-line result rather than a beat or a miss?
Reported earnings per share within ±2% of the consensus estimate. The band is set there because a tighter one classifies rounding as news, and a wider one swallows surprises that genuinely moved a stock.
Are the figures consolidated or standalone?
Consolidated where a company reports on that basis, standalone otherwise, with all money in ₹ crore. Figures are as filed by the company with the exchanges (NSE/BSE); they are not restated or adjusted.
What does the 8-quarter trend line show?
Quarterly net profit for the last eight quarters, oldest on the left, always ending on the quarter shown in the row. Two years covers both the seasonal shape of the business and its direction. The line breaks where a quarter is missing rather than drawing across the gap, so a break is a real absence of data and not a reported collapse.
How do I find only the companies that beat estimates in Q4 FY25?
Use the Result filter above the table and choose Beat, or sort by EPS surprise to rank every covered company by how far it landed from consensus. Both are reflected in the page URL, so a filtered view can be bookmarked or shared.

Figures are as reported by companies in their quarterly filings to the exchanges (NSE/BSE), in ₹ crore. Consolidated results are shown where a company reports them, otherwise standalone. Year-on-year and quarter-on-quarter growth is omitted where the comparison period was loss-making, since a percentage change from a negative base is not meaningful. Analyst consensus is an estimate, not a forecast of outcome.